This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Pea, F.
Right arrow Articles by Furlanut, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Pea, F.
Right arrow Articles by Furlanut, M.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, August 2005, p. 3550-3553, Vol. 49, No. 8
0066-4804/05/$08.00+0     doi:10.1128/AAC.49.8.3550-3553.2005
Copyright © 2005, American Society for Microbiology. All Rights Reserved.

Ceftazidime in Acute Myeloid Leukemia Patients with Febrile Neutropenia: Helpfulness of Continuous Intravenous Infusion in Maximizing Pharmacodynamic Exposure

Federico Pea,1* Pierluigi Viale,2 Daniela Damiani,3 Federica Pavan,1 Francesco Cristini,2 Renato Fanin,3 and Mario Furlanut1

Institute of Clinical Pharmacology and Toxicology, Department of Experimental and Clinical Pathology and Medicine,1 Clinic of Infectious Diseases, Department of Medical and Morphological Research,2 Chair of Hematology, Department of Medical and Morphologic Research, and Division of Hematology, Medical School, University of Udine, Udine, Italy3

Received 7 February 2005/ Returned for modification 24 March 2005/ Accepted 7 May 2005

The pharmacokinetic-pharmacodynamic profile of a fixed 6-g daily continuous intravenous infusion of ceftazidime was assessed in 20 febrile neutropenic patients with acute myeloid leukemia. Mean steady-state ceftazidime concentrations averaging 40 mg/liter from day 2 on ensured maximized pharmacodynamic exposure (values close to four to five times the MIC breakpoint against Pseudomonas aeruginosa). However, large intra- and interindividual pharmacokinetic variability was documented throughout the study period.

* Corresponding author. Mailing address: Institute of Clinical Pharmacology and Toxicology, DPMSC, University of Udine, P. le S. Maria della Misericordia 3, 33100 Udine, Italy. Phone and fax: 39 0432 559833. E-mail: federico.pea{at}med.uniud.it.

Antimicrobial Agents and Chemotherapy, August 2005, p. 3550-3553, Vol. 49, No. 8
0066-4804/05/$08.00+0     doi:10.1128/AAC.49.8.3550-3553.2005
Copyright © 2005, American Society for Microbiology. All Rights Reserved.



This article has been cited by other articles:

  • Lamoth, F., Buclin, T., Csajka, C., Pascual, A., Calandra, T., Marchetti, O. (2009). Reassessment of Recommended Imipenem Doses in Febrile Neutropenic Patients with Hematological Malignancies. Antimicrob. Agents Chemother. 53: 785-787 [Abstract] [Full Text]  
  • Nomura, K., Morikawa, N., Ikawa, K., Ikeda, K., Fujimoto, Y., Shimizu, D., Taniguchi, K., Shimura, K., Kanbayashi, Y., Komori, T., Matsumoto, Y., Fujita, N., Shimazaki, C., Taniwaki, M. (2008). Optimized dosage and frequency of cefozopran for patients with febrile neutropenia based on population pharmacokinetic and pharmacodynamic analysis. J Antimicrob Chemother 61: 892-900 [Abstract] [Full Text]  
  • Lau, W. K., Mercer, D., Itani, K. M., Nicolau, D. P., Kuti, J. L., Mansfield, D., Dana, A. (2006). Randomized, Open-Label, Comparative Study of Piperacillin-Tazobactam Administered by Continuous Infusion versus Intermittent Infusion for Treatment of Hospitalized Patients with Complicated Intra-Abdominal Infection. Antimicrob. Agents Chemother. 50: 3556-3561 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»